Erythroid gene suppression by NF-kappa B.
NF-kappa B/Rel transcription factors play essential roles to mediate the immune response and apoptosis, and they have also been implicated in cellular differentiation such as erythropoiesis. To elucidate the possible role(s) of NF-kappa B in erythroid gene regulation and erythropoiesis, we have carried out transient transfection studies of the human embryonic/fetal erythroid cell line K562 and mouse adult erythroid MEL cells. It is shown that tumor necrosis factor-alpha represses the transcription activity directed by either alpha or zeta globin promoter in a dose-dependent manner. Furthermore, different NF-kappa B family members could effectively repress the transfected alpha-like globin promoters in K562 as well as in MEL cells. The involvement of NF-kappa B pathway is supported by the ability of a NF-kappa B-specific, dominant negative mutant to block the tumor necrosis factor-alpha or p65-mediated suppression of the alpha-like globin promoter activities. The suppression appears to be mediated through cis-linked HS-40 enhancer. Finally, stably transfected K562 cells overexpressing p65 contain reduced amounts of the p45/NF-E2 RNA and functional NF-E2 proteins. Our studies have identified a new set of targets of NF-kappa B. We suggest that the relatively high activity of the NF-kappa B pathway in early erythroid progenitors is involved in the suppression of erythroid-specific genes. Later in differentiation, together with other changes, the decline of the amounts of the NF-kappa B family of factors leads to derepression and consequent increase of NF-E2, which in turn would activate a subset of erythroid-specific genes.
Liu
Jan-Jan
JJ
Institute of Molecular Biology, Academia Sinica, Nankang, Taiwan, Republic of China.
Hou
Shin-Chen
SC
Shen
C-K James
CK
D000818:Animals; D002460:Cell Line; D004247:DNA / Q000378:metabolism; D004268:DNA-Binding Proteins / Q000378:metabolism; D004622:Embryo, Mammalian; D004742:Enhancer Elements, Genetic / Q000235:genetics; D004912:Erythrocytes / Q000378:metabolism*; D050981:Erythroid-Specific DNA-Binding Factors; D004920:Erythropoiesis / Q000187:drug effects*; D015870:Gene Expression; D005786:Gene Expression Regulation / Q000187:drug effects*; D005914:Globins / Q000235:genetics; D049452:Green Fluorescent Proteins; D006801:Humans; D004915:Leukemia, Erythroblastic, Acute; D008156:Luciferases / Q000235:genetics; D008164:Luminescent Proteins / Q000235:genetics; D051379:Mice; D050983:NF-E2 Transcription Factor; D050984:NF-E2 Transcription Factor, p45 Subunit; D016328:NF-kappa B / Q000235:genetics / Q000494:pharmacology*; D011401:Promoter Regions, Genetic; D011994:Recombinant Proteins; D013489:Suppression, Genetic; D014157:Transcription Factors / Q000378:metabolism; D014162:Transfection; D014407:Tumor Cells, Cultured; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology
D004268:DNA-Binding Proteins; D050981:Erythroid-Specific DNA-Binding Factors; D008164:Luminescent Proteins; D050983:NF-E2 Transcription Factor; D050984:NF-E2 Transcription Factor, p45 Subunit; D016328:NF-kappa B; C494692:NFE2 protein, human; C494693:Nfe2 protein, mouse; D011994:Recombinant Proteins; D014157:Transcription Factors; D014409:Tumor Necrosis Factor-alpha; D049452:Green Fluorescent Proteins; D005914:Globins; D004247:DNA; D008156:Luciferases